The $200M upfront payment provides immediate liquidity but is offset by a contingent refund obligation tied to milestones. Monitor FMC's next earnings call for details on the Rimisoxafen development timeline and milestone probability.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 24 $11.32entry
- T+1 · 5mo ago 0.00%α −0.14% · $11.32
- T+5 · 5mo ago −3.27%α −4.98% · $10.95
- T+20 · 4mo ago +4.06%α +2.13% · $11.78
- T+60 · 2mo ago −9.89%α −12.73% · $10.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FMC entered Amendment No. 7 to its credit agreement to facilitate a $200M supply and license deal with Corteva Agriscience for the Rimisoxafen molecule. The amendment permits Corteva to take a first-priority lien on the related IP and releases that IP from the lenders' collateral pool, with a contingent refund obligation of up to $200M if milestones are not met. This is a routine credit-agreement amendment enabling a non-core asset monetization, no new debt is created, and the existing credit facility terms remain unchanged.
Key Financial Metrics
Key Facts
- FMC will receive a $200M upfront payment from Corteva for a license to Rimisoxafen-related IP.
- The payment is subject to a contingent refund obligation of up to $200M if certain milestones are not achieved.
- Corteva will receive a first-priority security interest in the Rimi IP to secure the refund obligation.
- The credit agreement amendment releases the Rimi IP from the lenders' collateral pool and permits the Corteva lien.
- No new debt is created; the existing credit facility's total capacity and terms remain unchanged.
- The amendment was approved by the Required Lenders and became effective June 16, 2026.
Financial Impact
FMC receives $200M upfront from Corteva, with a contingent refund obligation of up to $200M. No new debt or dilution.
Risk Factors
- Contingent refund obligation of up to $200M if milestones are not achieved, creating potential future cash outflow.
- Loss of collateral coverage for lenders on the Rimi IP could increase borrowing costs in future amendments.
- The deal does not address FMC's underlying operational or financial challenges that have driven recent stock declines.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-279416 |
| Document: d123428d8k.htm | 0001193125-26-279416 |
| Document: 0001193125-26-279416-index-headers.html | 0001193125-26-279416 |
| Document: 0001193125-26-279416-index.html | 0001193125-26-279416 |
| Document: 0001193125-26-279416.txt | 0001193125-26-279416 |
Track record
25 reports on FMC
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.91% at T+60 after the Apr 20, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $5.06 Now $5.23 +3.36% settles Nov 19
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $5.64 Now $5.23 −7.27% settles Nov 17
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $6.42 to $5.65 Now $5.23 −18.54% ▼ −11.99% −11.08% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $6.09 to $5.64 Now $5.23 −14.12% ▼ −7.39% −6.80% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $6.20 to $5.63 Now $5.23 −15.65% ▼ −9.19% −6.49% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $6.20 to $5.63 Now $5.23 −15.65% ▼ −9.19% −6.49% vs SPY
- Oct 29, 202618d ago 8-K Bearish 7/10 Entry $6.20 to $5.63 Now $5.23 +15.65% ▲ +9.19% +6.49% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 4/10 Entry $4.47 to $6.42 Now $5.23 +17.00% ▲ +43.62% +44.34% vs SPY
- Oct 21, 202626d ago 8-K Neutral 2/10 Entry $5.02 to $4.75 Now $5.23 +4.18% ▼ −5.38% −6.09% vs SPY
- Oct 21, 202626d ago 8-K Neutral 3/10 Entry $5.02 to $4.75 Now $5.23 +4.18% ▼ −5.38% −6.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers